Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	September 7, 2012 November 4, 2015

SUPPRELIN LA® (histrelin acetate)

LENGTH OF AUTHORIZATION: One implant per 12 months

REVIEW CRITERIA: (All of the following must be met for approval):

1. Age: Must be less than or equal to age 11 for girls or age 12 for boys, but two or older for all genders.
2. Diagnosis: Must have a diagnosis of Precocious Puberty (ICD-9 259.1; ICD-10 E22.8 – Precocious sexual development and puberty, not elsewhere classified). Diagnosis should be confirmed by all the following:
    a. Measurement of blood concentrations of total sex steroids (estrogens/testosterone).
    b. Measurement of LH and FSH after stimulation with a GnRH analog.
    c. Assessment of bone vs. chronological age.
3. Patient must have been evaluated and therapy prescribed by a pediatric endocrinologist
4. Trial and failure of either Lupron Ped Depot or intranasal Synarel.

QUANTITY LIMITATION:

Maximum of 1 implant per 12 months

DOSAGE AND ADMINISTRATION:

- The recommended dose of Supprelin LA is one implant every 12 months.
- Each implant contains 50 mg histrelin acetate. The implant is inserted subcutaneously in the inner aspect of the upper arm and provides continuous release of histrelin acetate (65 mcg/day) for 12 months of hormonal therapy.
- Supprelin LA should be removed after 12 months of therapy (the implant has been designed to allow for a few additional weeks of histrelin acetate release, in order to allow flexibility of medical appointments).
- At the time an implant is removed, another implant may be inserted to continue therapy.
- Discontinuation of Supprelin LA should be considered at the discretion of the physician and at the appropriate time point for the onset of puberty (approximately 11 years for females and 12 years for males).